All In The Family: Checkpoint Inhibitors Hold Promise In NSCLC
Executive Summary
The PD-1/PD-L1 inhibitors are at the forefront of development in lung cancer, and all eyes are on what implications the different approaches will have in terms of safety and efficacy.